E-resources
PDF-
Knight, Steven D; Adams, Nicholas D; Burgess, Joelle L; Chaudhari, Amita M; Darcy, Michael G; Donatelli, Carla A; Luengo, Juan I; Newlander, Ken A; Parrish, Cynthia A; Ridgers, Lance H; Sarpong, Martha A; Schmidt, Stanley J; Van Aller, Glenn S; Carson, Jeffrey D; Diamond, Melody A; Elkins, Patricia A; Gardiner, Christine M; Garver, Eric; Gilbert, Seth A; Gontarek, Richard R; Jackson, Jeffrey R; Kershner, Kevin L; Luo, Lusong; Raha, Kaushik; Sherk, Christian S; Sung, Chiu-Mei; Sutton, David; Tummino, Peter J; Wegrzyn, Ronald J; Auger, Kurt R; Dhanak, Dashyant
ACS medicinal chemistry letters, 04/2010, Volume: 1, Issue: 1Journal Article
Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-4-(4-pyridazinyl)-6-quinolinyl-3-pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models. Compound 1 is currently being evaluated in human clinical trials for the treatment of cancer.
